期刊文献+

生物来源的缩宫素注射液升压物质检查替代方法的研究 被引量:1

Study on alternative method for vasopressin impurity test of oxytocin injection from biological extraction
下载PDF
导出
摘要 目的 对生物来源缩宫素注射液的升压物质检查进行大鼠血压法和HPLC法的替代研究。方法 建立体外升压物质检查的HPLC法并进行方法验证,分别使用HPLC法和大鼠血压法对生物来源的缩宫素注射液样品和模拟样品进行升压物质检查。结果 在该文HPLC色谱条件下,升压素与相邻杂质峰之间的分离度均符合要求,在210~13 330 IU·L^(-1)范围内,升压素浓度与其色谱峰面积呈良好线性关系,r=0.999 9。HPLC法与现行标准中的生物检查法-大鼠血压法检测结果一致。结论 该法专属性好、灵敏、准确,可作为升压物质检查法代替现行标准中的大鼠血压法。 Aim To explore the alternative study on rat blood pressure method and HPLC method for vasopressin impurity test of oxytocin injection from biological extraction. Methods The HPLC method for the vasopressin impurity test in vitro was established and validated. The bio-extraction oxytocin injection samples and simulated samples were examined for vasopressin impurity by HPLC and rat blood pressure methods respectively. Results Vasopressin and adjacent impurity peaks were successfully separated by the established method. In the range of 210~ 13 330 IU·L^(-1) the concentration of vasopressin had a good linear relationship with its peak area with r= 0.999 9. The results of HPLC method were consistent with the biological examination method-rat blood pressure method in the current standard. Conclusions The method is proved to be specific,sensitive,and accurate,which can be used as a test method for vasopressin impurity to replace the rat blood pressure method in the current standard.
作者 郭龙静 杨泽岸 吴彦霖 蔡彤 高华 张媛 GUO Long-jing;YANG Ze-an;WU Yan-lin;CAI Tong;GAO Hua;ZHANG Yuan(National Institutes for Food and Drug Control,Division of Pharmacology,Beijing 102629,China)
出处 《中国药理学通报》 CAS CSCD 北大核心 2023年第4期794-799,共6页 Chinese Pharmacological Bulletin
基金 国家“重大新药创制”科技重大专项资助项目(No 2015ZX09303001)。
关键词 缩宫素 升压素 升压物质检查法 高效液相色谱 验证 方法替代 oxytocin vasopressin vasopressin impurity test high performance liquid chromatography validation alternative method
  • 相关文献

参考文献6

二级参考文献49

  • 1许明哲,尹利辉,胡昌勤.HPLC法测定他克莫司软膏剂含量及含量均匀度[J].中国抗生素杂志,2005,30(12):748-751. 被引量:16
  • 2王亚敏.生物检定在药品质量标准中的作用[J].中国生化药物杂志,2007,28(2):133-136. 被引量:11
  • 3Kinoshita Y, Yahata K, Yoshioka T, et al. Long - term renal preservation after brain death maintained with vasopressin and epinephrine [ J ] . Transpl Int, 1990,3 ( 1 ) : 15 - 18.
  • 4Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs [ J]. Transplantation, 2003,75 ( 4 ) :482 - 487.
  • 5Lindner KH, Haak T, Keller A, et al. Release of endogenous vasopressors during and after cardiopulmonary resuscitation [ J ]. Heart, 1996,75 (2) : 145 - 150.
  • 6Wyer PC ,Perera P,Jin Z, et al. Vasopressin or epinephrine for out - of- hospital cardiac arrest[ J]. Ann Emerg Med,2006,48 (1) :86 - 97.
  • 7American Heart Association ; American Academy of Pediatrics. 2005 American Heart Association (AHA) guidelines for cardiopuhnonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: neonatal resuscitation guidelines [ J ]. Circulation,2005, 112(24 Suppl) :IVI -203.
  • 8Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock [ J ]. Circulation, 1997,95(5):1122 -1125.
  • 9Leone M, Boyle WA. Decreased vasopressin responsiveness in vasodilatory septic shock - like conditions [ J ]. Crit Care Med, 2006,34 (4) :1126 - 1130.
  • 10Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock[ J]. Crit Care Med, 2004,32(3) :858 -873.

共引文献126

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部